clinical trial · NCT07204080
(TNX-1500) in Kidney Transplant Recipients
Ayman Al Jurdi, MD·phase2·not yet recruiting·n = 5
Kidney TransplantKidney Transplant Failure and RejectionImmunosuppressionImmunosuppression After Kidney TransplantationTNX-1500Kidney Transplant
brief summary
The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
started
Jul 1, 2026
primary completion
Sep 1, 2028
completion
Jun 30, 2029
last updated
Feb 25, 2026
official title
Phase II Clinical Trial Evaluating the Safety and Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol